Priming for local and systemic antibody memory responses to bovine respiratory syncytial virus: Effect of amount of virus, virus replication, route of administration and maternal antibodies

1989 ◽  
Vol 22 (2) ◽  
pp. 145-160 ◽  
Author(s):  
T.G. Kimman ◽  
F. Westenbrink ◽  
P.J. Straver
1999 ◽  
Vol 73 (1) ◽  
pp. 251-259 ◽  
Author(s):  
Ursula J. Buchholz ◽  
Stefan Finke ◽  
Karl-Klaus Conzelmann

ABSTRACT In order to generate recombinant bovine respiratory syncytial virus (BRSV), the genome of BRSV strain A51908, variant ATue51908, was cloned as cDNA. We provide here the sequence of the BRSV genome ends and of the entire L gene. This completes the sequence of the BRSV genome, which comprises a total of 15,140 nucleotides. To establish a vaccinia virus-free recovery system, a BHK-derived cell line stably expressing T7 RNA polymerase was generated (BSR T7/5). Recombinant BRSV was reproducibly recovered from cDNA constructs after T7 RNA polymerase-driven expression of antigenome sense RNA and of BRSV N, P, M2, and L proteins from transfected plasmids. Chimeric viruses in which the BRSV leader region was replaced by the human respiratory syncytial virus (HRSV) leader region replicated in cell culture as efficiently as their nonchimeric counterparts, demonstrating that allcis-acting sequences of the HRSV promoter are faithfully recognized by the BRSV polymerase complex. In addition, we report the successful recovery of a BRSV mutant lacking the complete NS2 gene, which encodes a nonstructural protein of unknown function. The NS2-deficient BRSV replicated autonomously and could be passaged, demonstrating that NS2 is not essential for virus replication in cell culture. However, growth of the mutant was considerably slower than and final infectious titers were reduced by a factor of at least 10 compared to wild-type BRSV, indicating that NS2 provides a supporting factor required for full replication capacity.


Vaccine ◽  
2004 ◽  
Vol 23 (5) ◽  
pp. 646-655 ◽  
Author(s):  
Sara Hägglund ◽  
Ke-Fei Hu ◽  
Lars Erik Larsen ◽  
Mikhayil Hakhverdyan ◽  
Jean-François Valarcher ◽  
...  

2007 ◽  
Vol 20 (1) ◽  
pp. 119-130 ◽  
Author(s):  
Sasha J. Fach ◽  
David K. Meyerholz ◽  
Jack M. Gallup ◽  
Mark R. Ackermann ◽  
Howard D. Lehmkuhl ◽  
...  

2009 ◽  
Vol 17 (1) ◽  
pp. 23-35 ◽  
Author(s):  
John W. Mapletoft ◽  
Laura Latimer ◽  
Lorne A. Babiuk ◽  
Sylvia van Drunen Littel-van den Hurk

ABSTRACT Bovine respiratory syncytial virus (BRSV) infects cells of the respiratory mucosa, so it is desirable to develop a vaccination strategy that induces mucosal immunity. To achieve this, various delivery routes were compared for formalin-inactivated (FI) BRSV formulated with CpG oligodeoxynucleotide (ODN) and polyphosphazene (PP). Intranasal delivery of the FI-BRSV formulation was superior to subcutaneous delivery in terms of antibody, cell-mediated, and mucosal immune responses, as well as reduction in virus replication after BRSV challenge. Although intranasal delivery of FI-BRSV also induced higher serum and lung antibody titers and gamma interferon (IFN-γ) production in the lungs than intranasal-subcutaneous and/or subcutaneous-intranasal prime-boost strategies, no significant differences were observed in cell-mediated immune responses or virus replication in the lungs of challenged mice. Interleukin 5 (IL-5), eotaxin, and eosinophilia were enhanced after BRSV challenge in the lungs of subcutaneously immunized mice compared to unvaccinated mice, but not in the lungs of mice immunized intranasally or through combinations of the intranasal and subcutaneous routes. These results suggest that two intranasal immunizations with FI-BRSV formulated with CpG ODN and PP are effective and safe as an approach to induce systemic and mucosal responses, as well to reduce virus replication after BRSV challenge. Furthermore, intranasal-subcutaneous and subcutaneous-intranasal prime-boost strategies were also safe and almost as efficacious. In addition to the implications for the development of a protective BRSV vaccine for cattle, formulation with CpG ODN and PP could also prove important in the development of a mucosal vaccine that induces protective immunity against human RSV.


Sign in / Sign up

Export Citation Format

Share Document